ZA200704168B - Lipid complexes coated with peg and their use - Google Patents

Lipid complexes coated with peg and their use Download PDF

Info

Publication number: ZA200704168B
Authority: ZA; South Africa
Prior art keywords: lipid; composition according; nucleic acid; group; helper
Prior art date: 2004-12-27

Application number

ZA200704168A

Other languages

English (en)

Inventor

Keil Oliver

Jorg Kaufmann

Original Assignee

Silence Therapeutics Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-12-27

Filing date

2007-05-22

Publication date

2008-05-28

2007-05-22 Application filed by Silence Therapeutics Ag filed Critical Silence Therapeutics Ag

2008-05-28 Publication of ZA200704168B publication Critical patent/ZA200704168B/en

Links

150000002632 lipids Chemical class 0.000 title claims description 202
239000000203 mixture Substances 0.000 claims description 198
150000001875 compounds Chemical class 0.000 claims description 148
102000039446 nucleic acids Human genes 0.000 claims description 83
108020004707 nucleic acids Proteins 0.000 claims description 83
150000007523 nucleic acids Chemical class 0.000 claims description 82
210000004027 cell Anatomy 0.000 claims description 47
125000005647 linker group Chemical group 0.000 claims description 45
-1 polypropylene Polymers 0.000 claims description 41
108020004459 Small interfering RNA Proteins 0.000 claims description 30
YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 claims description 27
CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 claims description 27
229940106189 ceramide Drugs 0.000 claims description 27
ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 claims description 27
VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 claims description 27
239000003795 chemical substances by application Substances 0.000 claims description 22
239000012528 membrane Substances 0.000 claims description 22
244000089409 Erythrina poeppigiana Species 0.000 claims description 21
108091030071 RNAI Proteins 0.000 claims description 21
235000009776 Rathbunia alamosensis Nutrition 0.000 claims description 21
101150054147 sina gene Proteins 0.000 claims description 21
238000000034 method Methods 0.000 claims description 20
239000002904 solvent Substances 0.000 claims description 20
125000000217 alkyl group Chemical group 0.000 claims description 19
239000000470 constituent Substances 0.000 claims description 19
108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 16
102000053642 Catalytic RNA Human genes 0.000 claims description 15
108090000994 Catalytic RNA Proteins 0.000 claims description 15
108091092562 ribozyme Proteins 0.000 claims description 15
108091023037 Aptamer Proteins 0.000 claims description 13
108090000623 proteins and genes Proteins 0.000 claims description 13
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
XLPHMKQBBCKEFO-DHYROEPTSA-N 2-azaniumylethyl [(2r)-2,3-bis(3,7,11,15-tetramethylhexadecanoyloxy)propyl] phosphate Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)CC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CC(C)CCCC(C)CCCC(C)CCCC(C)C XLPHMKQBBCKEFO-DHYROEPTSA-N 0.000 claims description 12
108020004414 DNA Proteins 0.000 claims description 12
235000018102 proteins Nutrition 0.000 claims description 12
102000004169 proteins and genes Human genes 0.000 claims description 12
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 11
230000000692 anti-sense effect Effects 0.000 claims description 11
108090000765 processed proteins & peptides Proteins 0.000 claims description 11
230000009368 gene silencing by RNA Effects 0.000 claims description 10
238000001727 in vivo Methods 0.000 claims description 10
239000008194 pharmaceutical composition Substances 0.000 claims description 9
125000000129 anionic group Chemical group 0.000 claims description 8
150000001450 anions Chemical class 0.000 claims description 8
238000012546 transfer Methods 0.000 claims description 8
102000040650 (ribonucleotides)n+m Human genes 0.000 claims description 7
102000053602 DNA Human genes 0.000 claims description 6
108091034117 Oligonucleotide Proteins 0.000 claims description 6
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 6
210000000170 cell membrane Anatomy 0.000 claims description 6
125000001117 oleyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 6
150000003904 phospholipids Chemical class 0.000 claims description 6
230000002378 acidificating effect Effects 0.000 claims description 5
210000001163 endosome Anatomy 0.000 claims description 5
102000004196 processed proteins & peptides Human genes 0.000 claims description 5
150000003431 steroids Chemical class 0.000 claims description 5
SHCCKWGIFIPGNJ-NSUCVBPYSA-N 2-aminoethyl [(2r)-2,3-bis[(z)-octadec-9-enoxy]propyl] hydrogen phosphate Chemical compound CCCCCCCC\C=C/CCCCCCCCOC[C@H](COP(O)(=O)OCCN)OCCCCCCCC\C=C/CCCCCCCC SHCCKWGIFIPGNJ-NSUCVBPYSA-N 0.000 claims description 4
WHYSLMADZBKFMB-QQUOVXPPSA-N N-hexadecyl-N-[(Z)-octadec-9-enyl]propanamide trihydrochloride Chemical compound Cl.Cl.Cl.CCCCCCCCCCCCCCCCN(C(=O)CC)CCCCCCCC\C=C/CCCCCCCC WHYSLMADZBKFMB-QQUOVXPPSA-N 0.000 claims description 4
239000004743 Polypropylene Substances 0.000 claims description 4
229920002472 Starch Polymers 0.000 claims description 4
DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims description 4
125000002252 acyl group Chemical group 0.000 claims description 4
239000012736 aqueous medium Substances 0.000 claims description 4
MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 claims description 4
125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 4
239000003814 drug Substances 0.000 claims description 4
210000005260 human cell Anatomy 0.000 claims description 4
210000004962 mammalian cell Anatomy 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 4
125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
102000040430 polynucleotide Human genes 0.000 claims description 4
108091033319 polynucleotide Proteins 0.000 claims description 4
239000002157 polynucleotide Substances 0.000 claims description 4
229920001155 polypropylene Polymers 0.000 claims description 4
229920002477 rna polymer Polymers 0.000 claims description 4
235000019698 starch Nutrition 0.000 claims description 4
239000008107 starch Substances 0.000 claims description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 3
101001007348 Arachis hypogaea Galactose-binding lectin Proteins 0.000 claims description 3
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 3
GCEXYQJNCWOTDC-UHFFFAOYSA-N N-dodecyl-N-tetradecylpropanamide trihydrochloride Chemical compound Cl.Cl.Cl.C(CCCCCCCCCCC)N(C(CC)=O)CCCCCCCCCCCCCC GCEXYQJNCWOTDC-UHFFFAOYSA-N 0.000 claims description 3
DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims description 3
239000006185 dispersion Substances 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 3
235000013922 glutamic acid Nutrition 0.000 claims description 3
239000004220 glutamic acid Substances 0.000 claims description 3
LVNGJLRDBYCPGB-LDLOPFEMSA-N (R)-1,2-distearoylphosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-LDLOPFEMSA-N 0.000 claims description 2
QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 claims description 2
OTGQIQQTPXJQRG-UHFFFAOYSA-N N-(octadecanoyl)ethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)NCCO OTGQIQQTPXJQRG-UHFFFAOYSA-N 0.000 claims description 2
YDNKGFDKKRUKPY-UHFFFAOYSA-N N-palmitoyldihydro-sphingosine Natural products CCCCCCCCCCCCCCCC(=O)NC(CO)C(O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-UHFFFAOYSA-N 0.000 claims description 2
108091081021 Sense strand Proteins 0.000 claims description 2
230000007935 neutral effect Effects 0.000 claims description 2
229960003330 pentetic acid Drugs 0.000 claims description 2
125000001288 lysyl group Chemical group 0.000 claims 1
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 72
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 48
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 36
239000002502 liposome Substances 0.000 description 31
230000015572 biosynthetic process Effects 0.000 description 27
238000003786 synthesis reaction Methods 0.000 description 27
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
239000000243 solution Substances 0.000 description 24
238000009472 formulation Methods 0.000 description 20
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 18
125000004432 carbon atom Chemical group C* 0.000 description 17
125000002091 cationic group Chemical group 0.000 description 16
229940093499 ethyl acetate Drugs 0.000 description 16
235000019439 ethyl acetate Nutrition 0.000 description 16
239000000047 product Substances 0.000 description 15
238000006243 chemical reaction Methods 0.000 description 13
239000002773 nucleotide Substances 0.000 description 11
229940113162 oleylamide Drugs 0.000 description 11
239000012074 organic phase Substances 0.000 description 11
239000007787 solid Substances 0.000 description 11
CHAQTRWDLCZRSS-ZPHPHTNESA-N (z)-n-hexadecyloctadec-9-en-1-amine Chemical compound CCCCCCCCCCCCCCCCNCCCCCCCC\C=C/CCCCCCCC CHAQTRWDLCZRSS-ZPHPHTNESA-N 0.000 description 10
229910052786 argon Inorganic materials 0.000 description 9
230000000694 effects Effects 0.000 description 8
230000003993 interaction Effects 0.000 description 8
125000003729 nucleotide group Chemical group 0.000 description 8
238000013461 design Methods 0.000 description 7
238000003818 flash chromatography Methods 0.000 description 7
238000000265 homogenisation Methods 0.000 description 7
239000007858 starting material Substances 0.000 description 7
125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 6
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
GKQLYSROISKDLL-UHFFFAOYSA-N EEDQ Chemical compound C1=CC=C2N(C(=O)OCC)C(OCC)C=CC2=C1 GKQLYSROISKDLL-UHFFFAOYSA-N 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
239000011734 sodium Substances 0.000 description 6
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 5
235000001014 amino acid Nutrition 0.000 description 5
150000001413 amino acids Chemical class 0.000 description 5
239000008365 aqueous carrier Substances 0.000 description 5
230000001413 cellular effect Effects 0.000 description 5
238000004587 chromatography analysis Methods 0.000 description 5
238000001125 extrusion Methods 0.000 description 5
239000011261 inert gas Substances 0.000 description 5
229920006395 saturated elastomer Polymers 0.000 description 5
238000004809 thin layer chromatography Methods 0.000 description 5
210000001519 tissue Anatomy 0.000 description 5
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
241001465754 Metazoa Species 0.000 description 4
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
239000012300 argon atmosphere Substances 0.000 description 4
IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 4
239000003480 eluent Substances 0.000 description 4
239000007788 liquid Substances 0.000 description 4
210000000056 organ Anatomy 0.000 description 4
229920000642 polymer Polymers 0.000 description 4
238000001890 transfection Methods 0.000 description 4
UDERCQOLHVKNBO-MTSUIVEXSA-N (2S)-6-amino-2-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]-N-dodecyl-N-tetradecylhexanamide trihydrochloride Chemical compound Cl.Cl.Cl.CCCCCCCCCCCCCCN(CCCCCCCCCCCC)C(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCNC(N)=N UDERCQOLHVKNBO-MTSUIVEXSA-N 0.000 description 3
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 3
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 3
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
108010078791 Carrier Proteins Proteins 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
239000005642 Oleic acid Substances 0.000 description 3
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
230000009471 action Effects 0.000 description 3
210000004102 animal cell Anatomy 0.000 description 3
238000013459 approach Methods 0.000 description 3
210000001124 body fluid Anatomy 0.000 description 3
230000000295 complement effect Effects 0.000 description 3
229940124447 delivery agent Drugs 0.000 description 3
HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 3
238000009826 distribution Methods 0.000 description 3
238000005516 engineering process Methods 0.000 description 3
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 3
239000000463 material Substances 0.000 description 3
230000007246 mechanism Effects 0.000 description 3
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 3
238000001262 western blot Methods 0.000 description 3
MVWPBNQGEGBGRF-IBGZPJMESA-N (2s)-3-(9h-fluoren-9-ylmethoxycarbonylamino)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound C1=CC=C2C(COC(=O)NC[C@H](NC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 MVWPBNQGEGBGRF-IBGZPJMESA-N 0.000 description 2
MDCPCLPRWLKUIQ-LURJTMIESA-N (2s)-4-azaniumyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]butanoate Chemical compound CC(C)(C)OC(=O)N[C@H](C([O-])=O)CC[NH3+] MDCPCLPRWLKUIQ-LURJTMIESA-N 0.000 description 2
QGLWBTPVKHMVHM-KTKRTIGZSA-N (z)-octadec-9-en-1-amine Chemical compound CCCCCCCC\C=C/CCCCCCCCN QGLWBTPVKHMVHM-KTKRTIGZSA-N 0.000 description 2
HNTGIJLWHDPAFN-UHFFFAOYSA-N 1-bromohexadecane Chemical compound CCCCCCCCCCCCCCCCBr HNTGIJLWHDPAFN-UHFFFAOYSA-N 0.000 description 2
108020000948 Antisense Oligonucleotides Proteins 0.000 description 2
241000283690 Bos taurus Species 0.000 description 2
FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
241000282472 Canis lupus familiaris Species 0.000 description 2
241000283707 Capra Species 0.000 description 2
241000700198 Cavia Species 0.000 description 2
241000282693 Cercopithecidae Species 0.000 description 2
241000283086 Equidae Species 0.000 description 2
241000282326 Felis catus Species 0.000 description 2
241000282412 Homo Species 0.000 description 2
239000000232 Lipid Bilayer Substances 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
102000015636 Oligopeptides Human genes 0.000 description 2
108010038807 Oligopeptides Proteins 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
102000014160 PTEN Phosphohydrolase Human genes 0.000 description 2
108010011536 PTEN Phosphohydrolase Proteins 0.000 description 2
241001494479 Pecora Species 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
241000700159 Rattus Species 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
241000282887 Suidae Species 0.000 description 2
241000251539 Vertebrata <Metazoa> Species 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
239000000074 antisense oligonucleotide Substances 0.000 description 2
238000012230 antisense oligonucleotides Methods 0.000 description 2
239000008346 aqueous phase Substances 0.000 description 2
230000008901 benefit Effects 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
239000000872 buffer Substances 0.000 description 2
230000003197 catalytic effect Effects 0.000 description 2
150000001805 chlorine compounds Chemical class 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
239000013078 crystal Substances 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
JRBPAEWTRLWTQC-UHFFFAOYSA-N dodecylamine Chemical compound CCCCCCCCCCCCN JRBPAEWTRLWTQC-UHFFFAOYSA-N 0.000 description 2
230000003511 endothelial effect Effects 0.000 description 2
RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 2
230000007717 exclusion Effects 0.000 description 2
238000004817 gas chromatography Methods 0.000 description 2
150000004820 halides Chemical class 0.000 description 2
231100000171 higher toxicity Toxicity 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
108020004999 messenger RNA Proteins 0.000 description 2
MZKSBYBYCXBNGA-UHFFFAOYSA-N n-dodecyltetradecan-1-amine Chemical compound CCCCCCCCCCCCCCNCCCCCCCCCCCC MZKSBYBYCXBNGA-UHFFFAOYSA-N 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
239000012071 phase Substances 0.000 description 2
239000013612 plasmid Substances 0.000 description 2
244000144977 poultry Species 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
238000012545 processing Methods 0.000 description 2
230000035484 reaction time Effects 0.000 description 2
238000010992 reflux Methods 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
239000000741 silica gel Substances 0.000 description 2
229910002027 silica gel Inorganic materials 0.000 description 2
229960001866 silicon dioxide Drugs 0.000 description 2
238000003756 stirring Methods 0.000 description 2
238000007910 systemic administration Methods 0.000 description 2
DPKBAXPHAYBPRL-UHFFFAOYSA-M tetrabutylazanium;iodide Chemical compound [I-].CCCC[N+](CCCC)(CCCC)CCCC DPKBAXPHAYBPRL-UHFFFAOYSA-M 0.000 description 2
210000005166 vasculature Anatomy 0.000 description 2
239000013603 viral vector Substances 0.000 description 2
AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
BGOFOVHACSQSIE-ZDUSSCGKSA-N (2s)-5-[bis[(2-methylpropan-2-yl)oxycarbonylamino]methylideneamino]-2-[(2-methylpropan-2-yl)oxycarbonylamino]pentanoic acid Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CCCNC(NC(=O)OC(C)(C)C)=NC(=O)OC(C)(C)C BGOFOVHACSQSIE-ZDUSSCGKSA-N 0.000 description 1
JYEVQYFWINBXJU-QFIPXVFZSA-N (2s)-6-(9h-fluoren-9-ylmethoxycarbonylamino)-2-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoic acid Chemical compound C1=CC=C2C(COC(=O)NCCCC[C@H](NC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 JYEVQYFWINBXJU-QFIPXVFZSA-N 0.000 description 1
LGGXTTVQTBPPLC-ULAWRXDQSA-N (4r,5s,6r,7r)-1,4,5,6,7,8-hexahydroxyoctan-3-one Chemical compound OCCC(=O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO LGGXTTVQTBPPLC-ULAWRXDQSA-N 0.000 description 1
BKHMAOXOKNEKHL-NNJYRKLXSA-N (5s)-2,3,5-triamino-8-(diaminomethylideneamino)-n-hexadecyl-n-[(z)-octadec-9-enyl]-4-oxooctanamide;trihydrochloride Chemical compound Cl.Cl.Cl.CCCCCCCCCCCCCCCCN(C(=O)C(N)C(N)C(=O)[C@@H](N)CCCNC(N)=N)CCCCCCCC\C=C/CCCCCCCC BKHMAOXOKNEKHL-NNJYRKLXSA-N 0.000 description 1
GPAYSHQGOZDCQX-QPLCGJKRSA-N (Z)-tetratriacont-9-enamide Chemical compound CCCCCCCCCCCCCCCCCCCCCCCC\C=C/CCCCCCCC(N)=O GPAYSHQGOZDCQX-QPLCGJKRSA-N 0.000 description 1
IVZSTQJPMCJHFE-ZPHPHTNESA-N (z)-n-hexadecyloctadec-9-enamide Chemical compound CCCCCCCCCCCCCCCCNC(=O)CCCCCCC\C=C/CCCCCCCC IVZSTQJPMCJHFE-ZPHPHTNESA-N 0.000 description 1
MWRBNPKJOOWZPW-NYVOMTAGSA-N 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine zwitterion Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-NYVOMTAGSA-N 0.000 description 1
FJLUATLTXUNBOT-UHFFFAOYSA-N 1-Hexadecylamine Chemical compound CCCCCCCCCCCCCCCCN FJLUATLTXUNBOT-UHFFFAOYSA-N 0.000 description 1
KOFZTCSTGIWCQG-UHFFFAOYSA-N 1-bromotetradecane Chemical compound CCCCCCCCCCCCCCBr KOFZTCSTGIWCQG-UHFFFAOYSA-N 0.000 description 1
YMLNWFCEWLDJPC-UHFFFAOYSA-N 2,2-diamino-N-hexadecyl-N-[(Z)-octadec-9-enyl]propanamide trihydrochloride Chemical compound Cl.Cl.Cl.C(CCCCCCCCCCCCCCC)N(C(C(C)(N)N)=O)CCCCCCCCC=C/CCCCCCCC YMLNWFCEWLDJPC-UHFFFAOYSA-N 0.000 description 1
101100294106 Caenorhabditis elegans nhr-3 gene Proteins 0.000 description 1
229940126657 Compound 17 Drugs 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
102000004533 Endonucleases Human genes 0.000 description 1
108010042407 Endonucleases Proteins 0.000 description 1
229910010082 LiAlH Inorganic materials 0.000 description 1
229910010084 LiAlH4 Inorganic materials 0.000 description 1
108090000301 Membrane transport proteins Proteins 0.000 description 1
102000003939 Membrane transport proteins Human genes 0.000 description 1
101710163270 Nuclease Proteins 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
239000004365 Protease Substances 0.000 description 1
108091028664 Ribonucleotide Proteins 0.000 description 1
108020004682 Single-Stranded DNA Proteins 0.000 description 1
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
PLZVEHJLHYMBBY-UHFFFAOYSA-N Tetradecylamine Chemical compound CCCCCCCCCCCCCCN PLZVEHJLHYMBBY-UHFFFAOYSA-N 0.000 description 1
125000003342 alkenyl group Chemical group 0.000 description 1
125000006193 alkinyl group Chemical group 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
150000001449 anionic compounds Chemical class 0.000 description 1
239000012062 aqueous buffer Substances 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
238000005842 biochemical reaction Methods 0.000 description 1
229920001222 biopolymer Polymers 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
150000001649 bromium compounds Chemical class 0.000 description 1
229960004424 carbon dioxide Drugs 0.000 description 1
PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000008859 change Effects 0.000 description 1
230000002925 chemical effect Effects 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
238000001816 cooling Methods 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
230000009260 cross reactivity Effects 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
239000003599 detergent Substances 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
238000001035 drying Methods 0.000 description 1
238000002296 dynamic light scattering Methods 0.000 description 1
238000004520 electroporation Methods 0.000 description 1
230000009881 electrostatic interaction Effects 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
239000012467 final product Substances 0.000 description 1
150000002222 fluorine compounds Chemical class 0.000 description 1
XHVRQBAHPBVMBL-UHFFFAOYSA-N hexadecan-1-amine Chemical compound CCCCCCCCCCCCCCCCN.CCCCCCCCCCCCCCCCN XHVRQBAHPBVMBL-UHFFFAOYSA-N 0.000 description 1
125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
150000004678 hydrides Chemical class 0.000 description 1
150000002430 hydrocarbons Chemical group 0.000 description 1
150000002433 hydrophilic molecules Chemical class 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
239000012535 impurity Substances 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
150000004694 iodide salts Chemical class 0.000 description 1
239000002479 lipoplex Substances 0.000 description 1
239000012280 lithium aluminium hydride Substances 0.000 description 1
238000011068 loading method Methods 0.000 description 1
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
210000003712 lysosome Anatomy 0.000 description 1
230000001868 lysosomic effect Effects 0.000 description 1
230000009061 membrane transport Effects 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000003950 pathogenic mechanism Effects 0.000 description 1
230000006320 pegylation Effects 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
125000005642 phosphothioate group Chemical group 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
239000002336 ribonucleotide Substances 0.000 description 1
125000002652 ribonucleotide group Chemical group 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
239000012047 saturated solution Substances 0.000 description 1
238000000926 separation method Methods 0.000 description 1
239000004055 small Interfering RNA Substances 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
235000011152 sodium sulphate Nutrition 0.000 description 1
238000000527 sonication Methods 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
GOQZIPJCBUYLIR-UHFFFAOYSA-N tert-butyl n-[n-[(2-methylpropan-2-yl)oxycarbonyl]-n'-(trifluoromethylsulfonyl)carbamimidoyl]carbamate Chemical compound CC(C)(C)OC(=O)NC(=NS(=O)(=O)C(F)(F)F)NC(=O)OC(C)(C)C GOQZIPJCBUYLIR-UHFFFAOYSA-N 0.000 description 1
AYEKOFBPNLCAJY-UHFFFAOYSA-O thiamine pyrophosphate Chemical compound CC1=C(CCOP(O)(=O)OP(O)(O)=O)SC=[N+]1CC1=CN=C(C)N=C1N AYEKOFBPNLCAJY-UHFFFAOYSA-O 0.000 description 1
230000032258 transport Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/906—Drug delivery
- Y10S977/907—Liposome
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
- Y10T428/2984—Microcapsule with fluid core [includes liposome]

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Biotechnology (AREA)
Biophysics (AREA)
Dispersion Chemistry (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Materials For Medical Uses (AREA)

ZA200704168A 2004-12-27 2007-05-22 Lipid complexes coated with peg and their use ZA200704168B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP04030846		2004-12-27

Publications (1)

Publication Number	Publication Date
ZA200704168B true ZA200704168B (en)	2008-05-28

Family

ID=36540272

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200704168A ZA200704168B (en)	2004-12-27	2007-05-22	Lipid complexes coated with peg and their use

Country Status (17)

Country	Link
US (2)	US8852472B2 (xx)
EP (2)	EP2992902A1 (xx)
JP (1)	JP5292572B2 (xx)
KR (1)	KR101366482B1 (xx)
CN (1)	CN101287497B (xx)
AU (1)	AU2005321469B2 (xx)
BR (1)	BRPI0519468A2 (xx)
CA (1)	CA2593032C (xx)
DK (1)	DK1830888T3 (xx)
ES (1)	ES2548515T3 (xx)
HK (2)	HK1119090A1 (xx)
IL (1)	IL183775A (xx)
MX (1)	MX2007007913A (xx)
PL (1)	PL1830888T3 (xx)
SG (1)	SG158175A1 (xx)
WO (1)	WO2006069782A2 (xx)
ZA (1)	ZA200704168B (xx)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK1527176T4 (en)	2002-08-05	2017-07-03	Silence Therapeutics Gmbh	ADDITIONAL NEW FORMS OF INTERFERRING RNA MOLECULES
AU2005237764B2 (en)	2004-05-05	2011-11-24	Silence Therapeutics Gmbh	Lipids, lipid complexes and use thereof
US8852472B2 (en)	2004-12-27	2014-10-07	Silence Therapeutics Gmbh	Coated lipid complexes and their use
KR101418367B1 (ko) *	2005-05-04	2014-07-25	녹손 파르마 아게	에이치엠지에이-결합 핵산
AU2007241370A1 (en) *	2006-04-20	2007-11-01	Silence Therapeutics Ag.	Lipoplex formulations for specific delivery to vascular endothelium
RU2553561C2 (ru) *	2006-07-21	2015-06-20	Сайленс Терапьютикс Аг	Средства ингибирования экспрессии протеинкиназы 3
JP2010513354A (ja)	2006-12-19	2010-04-30	ノヴォソムアクチェンゲゼルシャフト	トランスフェクションエンハンサー要素を含む脂質および脂質集合体
EP2323695B1 (en)	2008-08-19	2018-12-05	Nektar Therapeutics	Complexes of small-interfering nucleic acids
US8829179B2 (en)	2009-02-18	2014-09-09	Silence Therapeutics Gmbh	Means for inhibiting the expression of ANG2
US8916693B2 (en)	2009-09-17	2014-12-23	Nektar Therapeutics	Monoconjugated chitosans as delivery agents for small interfering nucleic acids
US8359883B2 (en) *	2009-11-13	2013-01-29	Hasmukh Dholakiya	Gemstone setting
WO2011120053A1 (en)	2010-03-26	2011-09-29	Mersana Therapeutics, Inc.	Modified polymers for delivery of polynucleotides, method of manufacture, and methods of use thereof
WO2011133658A1 (en)	2010-04-22	2011-10-27	Boston Medical Center Corporation	Compositions and methods for targeting and delivering therapeutics into cells
WO2012113413A1 (en) *	2011-02-21	2012-08-30	Curevac Gmbh	Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates
TW201726600A (zh)	2012-07-06	2017-08-01	協和醱酵麒麟有限公司	陽離子性脂質
WO2014018375A1 (en)	2012-07-23	2014-01-30	Xenon Pharmaceuticals Inc.	Cyp8b1 and uses thereof in therapeutic and diagnostic methods
ES2747762T3 (es)	2013-08-21	2020-03-11	Curevac Ag	Vacuna contra el virus respiratorio sincitial (RSV)
JP2016540769A (ja) *	2013-12-05	2016-12-28	サイレンス・セラピューティクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング	肺特異的送達用手段
US11097974B2 (en)	2014-07-31	2021-08-24	Corning Incorporated	Thermally strengthened consumer electronic glass and related systems and methods
US10611664B2 (en)	2014-07-31	2020-04-07	Corning Incorporated	Thermally strengthened architectural glass and related systems and methods
WO2016083623A1 (en) *	2014-11-28	2016-06-02	Silence Therapeutics Gmbh	Means for the treatment of pre-eclampsia
WO2017123573A2 (en)	2016-01-12	2017-07-20	Corning Incorporated	Thin thermally and chemically strengthened glass-based articles
US11795102B2 (en)	2016-01-26	2023-10-24	Corning Incorporated	Non-contact coated glass and related coating system and method
CN105687165A (zh) *	2016-03-14	2016-06-22	苏州博创康源生物技术有限公司	一种蛋白或多肽药物载药组织粘贴膜及其制备方法
CN105832709A (zh) *	2016-03-14	2016-08-10	苏州博创康源生物技术有限公司	一种核酸药物载药组织粘贴膜及其制备方法
CN106038516A (zh) *	2016-03-14	2016-10-26	苏州博创康源生物技术有限公司	一种化合物药物载药组织粘贴膜及其制备方法
CN105902523A (zh) *	2016-03-14	2016-08-31	苏州博创康源生物技术有限公司	一种载药组织粘贴膜及其制备方法
CN106038517A (zh) *	2016-03-14	2016-10-26	苏州博创康源生物技术有限公司	一种多糖药物载药组织粘贴膜及其制备方法
WO2018035387A1 (en)	2016-08-17	2018-02-22	The Broad Institute, Inc.	Novel crispr enzymes and systems
CN110114461A (zh)	2016-08-17	2019-08-09	博德研究所	新型crispr酶和***
WO2019040818A2 (en)	2017-08-24	2019-02-28	Corning Incorporated	GLASSES HAVING ENHANCED TEMPERATURE CAPABILITIES
CA3073848A1 (en)	2017-09-21	2019-03-28	The Broad Institute, Inc.	Systems, methods, and compositions for targeted nucleic acid editing
EP3710039A4 (en)	2017-11-13	2021-08-04	The Broad Institute, Inc.	METHODS AND COMPOSITIONS FOR CANCER TREATMENT BY TARGETING THE CLEC2D-KLRB1 PATH
TWI785156B (zh)	2017-11-30	2022-12-01	美商康寧公司	具有高熱膨脹係數及對於熱回火之優先破裂行為的非離子交換玻璃
US10968257B2 (en)	2018-04-03	2021-04-06	The Broad Institute, Inc.	Target recognition motifs and uses thereof
EP3833761A1 (en)	2018-08-07	2021-06-16	The Broad Institute, Inc.	Novel cas12b enzymes and systems
WO2020191102A1 (en)	2019-03-18	2020-09-24	The Broad Institute, Inc.	Type vii crispr proteins and systems
KR20210154825A (ko)	2019-04-23	2021-12-21	코닝 인코포레이티드	확정 응력 프로파일을 갖는 유리 라미네이트 및 그 제조방법
US20220220469A1 (en)	2019-05-20	2022-07-14	The Broad Institute, Inc.	Non-class i multi-component nucleic acid targeting systems
WO2021016075A1 (en)	2019-07-19	2021-01-28	Flagship Pioneering Innovations Vi, Llc	Recombinase compositions and methods of use
CN116811379A (zh)	2019-08-06	2023-09-29	康宁股份有限公司	具有用于阻止裂纹的埋入式应力尖峰的玻璃层压体及其制造方法
CN115667531A (zh)	2020-03-24	2023-01-31	世代生物公司	非病毒DNA载体和其用于表达戈谢（Gaucher）治疗剂的用途
CN115667530A (zh)	2020-03-24	2023-01-31	世代生物公司	非病毒dna载体和其用于表达因子ix治疗剂的用途
CN116322760A (zh)	2020-05-20	2023-06-23	旗舰创业创新第六有限责任公司	冠状病毒抗原组合物及其用途
EP4153223A1 (en)	2020-05-20	2023-03-29	Flagship Pioneering Innovations VI, LLC	Immunogenic compositions and uses thereof
IL298539A (en)	2020-05-29	2023-01-01	Flagship Pioneering Innovations Vi Llc	trem compositions and methods related thereto
US20230203509A1 (en)	2020-05-29	2023-06-29	Flagship Pioneering Innovations Vi, Llc	Trem compositions and methods relating thereto
CA3189740A1 (en)	2020-07-27	2022-02-03	Anjarium Biosciences Ag	Compositions of dna molecules, methods of making therefor, and methods of use thereof
IL300947A (en)	2020-09-03	2023-04-01	Flagship Pioneering Innovations Vi Llc	Immunogenic compositions and uses thereof
IL303886A (en)	2020-12-23	2023-08-01	Flagship Pioneering Inc	Modified TREMS vehicles and their uses
WO2022212784A1 (en)	2021-03-31	2022-10-06	Flagship Pioneering Innovations V, Inc.	Thanotransmission polypeptides and their use in treating cancer
WO2022223556A1 (en)	2021-04-20	2022-10-27	Anjarium Biosciences Ag	Compositions of dna molecules encoding amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase, methods of making thereof, and methods of use thereof
US20240226324A1 (en)	2021-04-27	2024-07-11	Generation Bio Co.	Non-viral dna vectors expressing therapeutic antibodies and uses thereof
EP4329884A1 (en)	2021-04-27	2024-03-06	Generation Bio Co.	Non-viral dna vectors expressing anti-coronavirus antibodies and uses thereof
CN113372226B (zh) *	2021-06-08	2023-05-26	深圳市人民医院	一种脂质分子、脂质纳米粒及其制备方法和应用
WO2023009547A1 (en)	2021-07-26	2023-02-02	Flagship Pioneering Innovations Vi, Llc	Trem compositions and uses thereof
CA3232635A1 (en)	2021-09-17	2023-03-23	Flagship Pioneering Innovations Vi, Llc	Compositions and methods for producing circular polyribonucleotides
CA3235625A1 (en)	2021-10-18	2023-04-27	Flagship Pioneering Innovations Vi, Llc	Compositions and methods for purifying polyribonucleotides
AU2022383068A1 (en)	2021-11-08	2024-05-02	Orna Therapeutics, Inc.	Lipid nanoparticle compositions for delivering circular polynucleotides
IL312799A (en)	2021-11-24	2024-07-01	Flagship Pioneering Innovations Vi Llc	Immunogenic compositions of varicella-zoster virus and uses thereof
AU2022397300A1 (en)	2021-11-24	2024-06-27	Flagship Pioneering Innovations Vi, Llc	Immunogenic compositions and their uses
KR20240117569A (ko)	2021-11-24	2024-08-01	플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨	코로나바이러스 면역원 조성물 및 그의 용도
KR20240118174A (ko)	2021-12-17	2024-08-02	플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨	변성 조건 하에서의 원형 rna의 풍부화를 위한 방법
TW202340461A (zh)	2021-12-22	2023-10-16	美商旗艦先鋒創新有限責任公司	用於純化多核糖核苷酸之組成物和方法
TW202342064A (zh)	2021-12-23	2023-11-01	美商旗艦先鋒創新有限責任公司	編碼抗融合多肽之環狀多核糖核苷酸
WO2023135273A2 (en)	2022-01-14	2023-07-20	Anjarium Biosciences Ag	Compositions of dna molecules encoding factor viii, methods of making thereof, and methods of use thereof
WO2023177655A1 (en)	2022-03-14	2023-09-21	Generation Bio Co.	Heterologous prime boost vaccine compositions and methods of use
WO2023183616A1 (en)	2022-03-25	2023-09-28	Senda Biosciences, Inc.	Novel ionizable lipids and lipid nanoparticles and methods of using the same
WO2023196818A1 (en)	2022-04-04	2023-10-12	The Regents Of The University Of California	Genetic complementation compositions and methods
WO2023196634A2 (en)	2022-04-08	2023-10-12	Flagship Pioneering Innovations Vii, Llc	Vaccines and related methods
WO2023220083A1 (en)	2022-05-09	2023-11-16	Flagship Pioneering Innovations Vi, Llc	Trem compositions and methods of use for treating proliferative disorders
WO2023220729A2 (en)	2022-05-13	2023-11-16	Flagship Pioneering Innovations Vii, Llc	Double stranded dna compositions and related methods
WO2023239756A1 (en)	2022-06-07	2023-12-14	Generation Bio Co.	Lipid nanoparticle compositions and uses thereof
WO2023250112A1 (en)	2022-06-22	2023-12-28	Flagship Pioneering Innovations Vi, Llc	Compositions of modified trems and uses thereof
WO2024030856A2 (en)	2022-08-01	2024-02-08	Flagship Pioneering Innovations Vii, Llc	Immunomodulatory proteins and related methods
WO2024035952A1 (en)	2022-08-12	2024-02-15	Remix Therapeutics Inc.	Methods and compositions for modulating splicing at alternative splice sites
WO2024040222A1 (en)	2022-08-19	2024-02-22	Generation Bio Co.	Cleavable closed-ended dna (cedna) and methods of use thereof
WO2024049979A2 (en)	2022-08-31	2024-03-07	Senda Biosciences, Inc.	Novel ionizable lipids and lipid nanoparticles and methods of using the same
WO2024077191A1 (en)	2022-10-05	2024-04-11	Flagship Pioneering Innovations V, Inc.	Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
WO2024097664A1 (en)	2022-10-31	2024-05-10	Flagship Pioneering Innovations Vi, Llc	Compositions and methods for purifying polyribonucleotides
WO2024102677A1 (en)	2022-11-08	2024-05-16	Orna Therapeutics, Inc.	Circular rna compositions
WO2024102730A1 (en)	2022-11-08	2024-05-16	Orna Therapeutics, Inc.	Lipids and nanoparticle compositions for delivering polynucleotides
WO2024102762A1 (en)	2022-11-08	2024-05-16	Orna Therapeutics, Inc.	Lipids and lipid nanoparticle compositions for delivering polynucleotides
WO2024102799A1 (en)	2022-11-08	2024-05-16	Flagship Pioneering Innovations Vi, Llc	Compositions and methods for producing circular polyribonucleotides
WO2024119103A1 (en)	2022-12-01	2024-06-06	Generation Bio Co.	Lipid nanoparticles comprising nucleic acids and lipid-anchored polymers
WO2024119039A2 (en)	2022-12-01	2024-06-06	Generation Bio Co.	Stealth lipid nanoparticles and uses thereof
WO2024119074A1 (en)	2022-12-01	2024-06-06	Generation Bio Co.	Stealth lipid nanoparticle compositions for cell targeting
WO2024119051A1 (en)	2022-12-01	2024-06-06	Generation Bio Co.	Novel polyglycerol-conjugated lipids and lipid nanoparticle compositions comprising the same
WO2024129988A1 (en)	2022-12-14	2024-06-20	Flagship Pioneering Innovations Vii, Llc	Compositions and methods for delivery of therapeutic agents to bone
US20240238473A1 (en)	2023-01-09	2024-07-18	Beth Israel Deaconess Medical Center, Inc.	Recombinant nucleic acid molecules and their use in wound healing
WO2024151583A2 (en)	2023-01-09	2024-07-18	Flagship Pioneering Innovations Vii, Llc	Vaccines and related methods
WO2024151687A1 (en)	2023-01-09	2024-07-18	Flagship Pioneering Innovations V, Inc.	Genetic switches and their use in treating cancer
WO2024151685A1 (en)	2023-01-09	2024-07-18	Beth Israel Deaconess Medical Center, Inc.	Recombinant nucleic acid molecules and their use in wound healing
US20240269263A1 (en)	2023-02-06	2024-08-15	Flagship Pioneering Innovations Vii, Llc	Immunomodulatory compositions and related methods

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2763958B2 (ja)	1990-06-11	1998-06-11	ネクスターファーマスーティカルズ，インコーポレイテッド	核酸リガンド
GB2270920B (en)	1992-09-25	1997-04-02	Univ Keele	Alginate-bioactive agent conjugates
FR2698628B1 (fr)	1992-12-02	1995-02-17	Fournier Ind & Sante	Analogues de 15-déoxyspergualine, leur procédé de préparation et leur utilisation en thérapeutique.
US5504103A (en)	1993-08-25	1996-04-02	Eli Lilly And Company	Inhibition of phosphatidylinositol 3-kinase with 17 β-hydroxywortmannin and analogs thereof
US5777153A (en)	1994-07-08	1998-07-07	Gilead Sciences, Inc.	Cationic lipids
US5820873A (en) *	1994-09-30	1998-10-13	The University Of British Columbia	Polyethylene glycol modified ceramide lipids and liposome uses thereof
US5885613A (en) *	1994-09-30	1999-03-23	The University Of British Columbia	Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US7422902B1 (en)	1995-06-07	2008-09-09	The University Of British Columbia	Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
EP1489184A1 (en)	1995-06-07	2004-12-22	Inex Pharmaceutical Corp.	Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
CA2227373A1 (en)	1995-07-21	1997-02-06	Promega Biosciences, Inc.	Novel amide-based cationic lipids
EP0934331B1 (de)	1996-08-30	2002-11-27	Jens Peter Fürste	Spiegelselektion und spiegelevolution von nucleinsäuren
US5849902A (en)	1996-09-26	1998-12-15	Oligos Etc. Inc.	Three component chimeric antisense oligonucleotides
US5989912A (en)	1996-11-21	1999-11-23	Oligos Etc. Inc.	Three component chimeric antisense oligonucleotides
CA2217550A1 (en)	1996-10-22	1998-04-22	F. Hoffmann-La Roche Ag	Cationic lipids for gene therapy
US6358523B1 (en)	1996-12-06	2002-03-19	The Regents Of The University Of California	Macromolecule-lipid complexes and methods for making and regulating
AU6949098A (en)	1997-04-04	1998-10-30	Valentis, Inc.	Improved methods of delivery using cationic lipids and helper lipids
WO1998051285A2 (en)	1997-05-15	1998-11-19	Genzyme Corporation	Cationic amphiphile formulations
PE79099A1 (es)	1997-06-13	1999-08-24	Lilly Co Eli	Formulaciones de insulina estables
US6395713B1 (en)	1997-07-23	2002-05-28	Ribozyme Pharmaceuticals, Inc.	Compositions for the delivery of negatively charged molecules
US20030073640A1 (en) *	1997-07-23	2003-04-17	Ribozyme Pharmaceuticals, Inc.	Novel compositions for the delivery of negatively charged molecules
AU8525098A (en) *	1997-07-24	1999-02-16	Inex Pharmaceuticals Corporation	Liposomal compositions for the delivery of nucleic acid catalysts
US6150345A (en)	1998-08-10	2000-11-21	Regents Of The University Of California	Methods for promoting survival of myelin producing cells
FR2788275B1 (fr)	1999-01-11	2002-06-14	Lipha	((aminoiminomethyl)amino) alcane carboxamides et leurs applications en therapeutique
DE19956568A1 (de)	1999-01-30	2000-08-17	Roland Kreutzer	Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
US7015040B2 (en) *	1999-02-26	2006-03-21	Mirus Bio Corporation	Intravascular delivery of nucleic acid
AU5173400A (en)	1999-05-28	2000-12-18	Sugen, Inc.	Protein kinases
EP1064944A1 (en)	1999-06-25	2001-01-03	Schering Aktiengesellschaft	Protein kinase N inhibitor comprising Fasudil
AU769357B2 (en) *	1999-07-15	2004-01-22	University Of British Columbia, The	Methods for preparation of lipid-encapsulated therapeutic agents
US6133032A (en)	1999-09-09	2000-10-17	Isis Pharmaceutical Inc.	Antisense modulation of PI3 kinase p110 beta expression
WO2001075164A2 (en)	2000-03-30	2001-10-11	Whitehead Institute For Biomedical Research	Rna sequence-specific mediators of rna interference
WO2001074397A1 (fr)	2000-03-31	2001-10-11	Kirin Beer Kabushiki Kaisha	Preparation en poudre destinee a etre administree par les muqueuses comprenant un medicament de forme polymere et presentant une stabilite de conservation amelioree
AU5454801A (en) *	2000-04-20	2001-11-07	Univ British Columbia	Methods of enhancing splp-mediated transfection using endosomal membrane destabilizers
CA2426244A1 (en) *	2000-10-25	2002-05-02	The University Of British Columbia	Lipid formulations for target delivery
DK2813582T3 (en)	2000-12-01	2017-07-31	Max-Planck-Gesellschaft Zur Förderung Der Wss E V	Small RNA molecules that mediate RNA interference
US20030135033A1 (en)	2002-01-04	2003-07-17	Anke Klippel-Giese	Compounds and methods for the identification and/ or validation of a target
EP1432724A4 (en)	2002-02-20	2006-02-01	Sirna Therapeutics Inc	RNA inhibition mediated inhibition of MAP KINASE GENES
US20040156816A1 (en)	2002-08-06	2004-08-12	David Anderson	Lipid-drug complexes in reversed liquid and liquid crystalline phases
EP1536827B1 (en)	2002-08-14	2009-01-07	Silence Therapeutics Aktiengesellschaft	Use of protein kinase n beta
EP1393742A1 (en)	2002-08-14	2004-03-03	atugen AG	Use of protein kinase N beta
US7635770B2 (en)	2002-11-14	2009-12-22	Dharmacon, Inc.	siRNA targeting protein kinase N-3 (PKN-3)
EP2151507B1 (en)	2002-12-20	2013-02-13	Celera Corporation	Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof
WO2005019258A2 (en)	2003-08-11	2005-03-03	Genentech, Inc.	Compositions and methods for the treatment of immune related diseases
ES2321841T3 (es) *	2003-08-26	2009-06-12	Smithkline Beecham Corporation	Copolimeros heterofuncionales de glicerol y polietilenglicol, sus conjugados y composiciones.
AU2005237764B2 (en)	2004-05-05	2011-11-24	Silence Therapeutics Gmbh	Lipids, lipid complexes and use thereof
AU2005277186A1 (en)	2004-08-20	2006-03-02	The Johns Hopkins University	Methods for treatment of angiogenesis
US20060159737A1 (en)	2004-11-19	2006-07-20	Steffen Panzner	Pharmaceutical compositions for local administration
US8852472B2 (en)	2004-12-27	2014-10-07	Silence Therapeutics Gmbh	Coated lipid complexes and their use
WO2006074546A1 (en)	2005-01-13	2006-07-20	Protiva Biotherapeutics, Inc.	Lipid encapsulated interfering rna
AU2007241370A1 (en)	2006-04-20	2007-11-01	Silence Therapeutics Ag.	Lipoplex formulations for specific delivery to vascular endothelium
AU2007241369A1 (en)	2006-04-20	2007-11-01	Silence Therapeutics Ag	Means for inhibiting the expression of CD31
RU2553561C2 (ru)	2006-07-21	2015-06-20	Сайленс Терапьютикс Аг	Средства ингибирования экспрессии протеинкиназы 3

2005
- 2005-12-27 US US11/722,948 patent/US8852472B2/en not_active Expired - Fee Related
- 2005-12-27 CN CN2005800450816A patent/CN101287497B/zh not_active Expired - Fee Related
- 2005-12-27 ES ES05822677.0T patent/ES2548515T3/es active Active
- 2005-12-27 WO PCT/EP2005/014074 patent/WO2006069782A2/en active Search and Examination
- 2005-12-27 BR BRPI0519468-7A patent/BRPI0519468A2/pt active Search and Examination
- 2005-12-27 MX MX2007007913A patent/MX2007007913A/es active IP Right Grant
- 2005-12-27 EP EP15179144.9A patent/EP2992902A1/en not_active Withdrawn
- 2005-12-27 CA CA2593032A patent/CA2593032C/en not_active Expired - Fee Related
- 2005-12-27 JP JP2007548751A patent/JP5292572B2/ja not_active Expired - Fee Related
- 2005-12-27 PL PL05822677T patent/PL1830888T3/pl unknown
- 2005-12-27 KR KR1020077014611A patent/KR101366482B1/ko active IP Right Grant
- 2005-12-27 AU AU2005321469A patent/AU2005321469B2/en not_active Ceased
- 2005-12-27 DK DK05822677.0T patent/DK1830888T3/en active
- 2005-12-27 EP EP05822677.0A patent/EP1830888B1/en not_active Not-in-force
- 2005-12-27 SG SG200908620-8A patent/SG158175A1/en unknown
2007
- 2007-05-22 ZA ZA200704168A patent/ZA200704168B/en unknown
- 2007-06-07 IL IL183775A patent/IL183775A/en not_active IP Right Cessation
2008
- 2008-12-05 HK HK08113257.3A patent/HK1119090A1/xx not_active IP Right Cessation
2014
- 2014-10-06 US US14/507,045 patent/US9387262B2/en not_active Expired - Fee Related
2016
- 2016-09-07 HK HK16110655.7A patent/HK1222541A1/zh unknown

Also Published As

Publication number	Publication date
CA2593032C (en)	2015-12-22
KR101366482B1 (ko)	2014-02-21
PL1830888T3 (pl)	2015-12-31
MX2007007913A (es)	2007-08-14
US9387262B2 (en)	2016-07-12
JP2008525514A (ja)	2008-07-17
BRPI0519468A2 (pt)	2009-01-27
WO2006069782A2 (en)	2006-07-06
DK1830888T3 (en)	2015-10-19
AU2005321469A1 (en)	2006-07-06
IL183775A (en)	2016-12-29
ES2548515T3 (es)	2015-10-19
HK1119090A1 (en)	2009-02-27
CN101287497B (zh)	2013-03-06
US8852472B2 (en)	2014-10-07
JP5292572B2 (ja)	2013-09-18
EP2992902A1 (en)	2016-03-09
KR20070090956A (ko)	2007-09-06
IL183775A0 (en)	2007-09-20
HK1222541A1 (zh)	2017-07-07
EP1830888B1 (en)	2015-08-05
CA2593032A1 (en)	2006-07-06
AU2005321469B2 (en)	2012-04-05
WO2006069782A9 (en)	2009-04-30
US20150031752A1 (en)	2015-01-29
US20100062967A1 (en)	2010-03-11
CN101287497A (zh)	2008-10-15
SG158175A1 (en)	2010-01-29
WO2006069782A3 (en)	2007-04-12
EP1830888A2 (en)	2007-09-12

Publication	Publication Date	Title
US9387262B2 (en)	2016-07-12	Coated lipid complexes and their use
US10155945B2 (en)	2018-12-18	Method of producing lipid nanoparticles for drug delivery
US8956572B2 (en)	2015-02-17	Single use system for sterilely producing lipid-nucleic acid particles
AU2005237764B2 (en)	2011-11-24	Lipids, lipid complexes and use thereof
EP4331681A2 (en)	2024-03-06	Method for delivering activators to cells
EP2068936B1 (en)	2016-06-22	Means and methods of enhancing delivery to biological systems
Neuberg et al.	2019	Design and evaluation of ionizable peptide amphiphiles for siRNA delivery
EP3395797A1 (en)	2018-10-31	Compounds as cationic lipids
AU8006400B2 (xx)	2004-12-23